NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

SIGA Technologies, Inc. (SIGA) Stock Analysis

SIGA Technologies, Inc. (SIGA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

SIGA

$3.29

+$0.06 (+1.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SIGA with… →

SIGA Key Statistics

As of Sep 4, 2026
Trading
Open
$3.20
Previous Close
$3.23
Day's Range
3.10–3.32
52-Week Range
2.83–9.45
Volume
899.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.89
Valuation
Market Cap
$236.39M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.05
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.37
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.04
Financials (FY)
Revenue (FY)
$94.57M−31.82%
Net Income (FY)
$23.28M−60.69%
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
71.85M
1-Year Return
−56.19%
Dividend and dates
Ex-Dividend Date
April 7, 2026
Earnings Date
November 5, 2026
Avg Volume
701.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SIGA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.13%
2025+12.27%
2024+15.21%
2023−17.64%
2022+4.16%
2021+3.44%
2020+52.41%
2019−39.62%
2018+62.89%
2017+68.40%
2016 (partial year)+32.72%

As of September 4, 2026.

SIGA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$94.57M$23.28M24.6%
2024$138.72M$59.21M42.7%
2023$139.92M$68.07M48.6%
2022$110.78M$33.90M30.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$94.57M$64.87M$23.70M$23.28M24.6%
2024$138.72M$107.43M$69.98M$59.21M42.7%
2023$139.92M$122.09M$83.62M$68.07M48.6%
2022$110.78M$100.34M$42.70M$33.90M30.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SIGA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricSIGADrug Manufacturers - Specialty & Generic medianvs median
P/S ratio4.412.3092% above
Profit margin−5.19%−3.14%2.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

SIGA Technologies, Inc. (SIGA) carries a market capitalisation of $236.39M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 49.

The most recent close on file for SIGA is $3.29, dated September 4, 2026. That is +$0.06 (+1.86%) against the previous close. Over the past 52 weeks the price has ranged from $2.83 to $9.45. The latest close sits 16.25% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $94.57M. Against the prior fiscal year total of $138.72M, that is a change of −31.82%. The same year closed with net income of $23.28M. That is −60.69% against the prior fiscal year. The reported profit margin is −5.19%. That is 2.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −0.04.

Across the 4 fiscal years on file, revenue moves from $110.78M in 2022 to $94.57M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 3.05. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.37. The price-to-sales ratio is 4.41. On price-to-sales that is 91.85% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −56.19%. Measured over 10 years, that is +7.18% a year compounded. The reported beta is 0.89. Annualized volatility over the trailing 10 years is 59.49%.

Growth & Income

No dividend is on file for SIGA.

The strongest complete calendar year on file is 2017 at +68.40%; the weakest is 2019 at −39.62%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the price is −39.13% year to date.

Peer Comparison

SIGA Technologies, Inc. (SIGA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SIGA Technologies, Inc. SIGA $236.39M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. SIGA Technologies, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About SIGA Technologies, Inc.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.

Visit website →